|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
This paper is a review of studies using these novel markers in order to determine whether prostate cancer patients with the following characteristics have more aggressive cancer than those without: a) high serum levels of cathepsin B, survivin, Her - 2 / neu, IGFBP-2; b) low serum stefin A, IGFBP-3, c) positive immuno-staining of primary tumors for Her-2/neu, survivin and cathepsin B / stefin A ratio > 1 and d) gene expression of AMACR, HER-2/neu, high Bcl-2: Bax ratio and EZH2 in cancer cells.
|
18405443 |
2008 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Here we show that androgen deprivation therapy (ADT), a widely used treatment for advanced prostate cancer, induces a senescence-associated secretory phenotype in prostate cancer epithelial cells, indicated by increases in senescence-associated β-galactosidase activity, heterochromatin protein 1β foci, and expression of cathepsin B and insulin-like growth factor binding protein 3.
|
21677876 |
2011 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
We demonstrated the importance of cathepsin B degradable linker from the context of drug content and different prostate cancer cell lines.
|
28913790 |
2017 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
RD-N, an aminomethylated derivative of riccardin D, is a lysosomotropic agent that can trigger lysosomal membrane permeabilization followed by cathepsin B (CTSB)-dependent apoptosis in prostate cancer (PCa) cells, but the underlying mechanisms remain unknown.
|
30565390 |
2019 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to determine the relationship of CB and stefin A (cystatin A) mRNA localization to the Gleason grading system for histologic scores in the hope of distinguishing aggressive and less aggressive variants of prostate cancer.
|
10652560 |
2000 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
In this study, the therapeutic potential of siRNA-mediated targeting of matrix metalloproteinase-9 (MMP-9), urokinase plasminogen activator receptor (uPAR), and cathepsin B (CB) in prostate cancer was carried out using single and bi-cistronic siRNA-expressing constructs.
|
20448670 |
2010 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
Together, these results demonstrate the critical role of MTA1 as an upstream regulator of CTSB-mediated events associated with cell invasiveness and raise the possibility that targeting MTA1/CTSB signaling in the tumor may prevent the development of bone metastasis in prostate cancer.
|
30027683 |
2018 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In contrast, immunostaining of glioma tissue for CD68 and for cathepsin B may be used for prognosis of survival in these patients.
|
19661345 |
2009 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Mechanism of p27 upregulation induced by downregulation of cathepsin B and uPAR in glioma.
|
21840777 |
2011 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
uPAR and cathepsin B-mediated compartmentalization of JNK regulates the migration of glioma-initiating cells.
|
24699410 |
2014 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our results show that downregulation of cathepsin B and uPAR alone and in combination inhibit glioma cell adhesion by downregulating CD151 and its associated signaling molecules in vitro and in vivo.
|
22495828 |
2013 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Glioma is the most commonly diagnosed primary brain tumor and is characterized by invasive and infiltrative behavior. uPAR and cathepsin B are known to be overexpressed in high-grade gliomas and are strongly correlated with invasive cancer phenotypes.
|
21060833 |
2010 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Radiation treatment significantly enhanced uPAR and cathepsin B levels in glioma-initiating cells.
|
22573309 |
2012 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We observed progressive reductions in levels of the protease inhibitor cystatin C, an inhibitor of cathepsin B with corresponding increases in the malignancy of glioma cell lines, implying an inverse correlation between cystatin C and tumor grade.
|
12483523 |
2002 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results demonstrate the potential of pMU and pMC as therapeutic candidates for the treatment of glioma.
|
22076676 |
2012 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Considering the existence of integrin inhibitor-resistant cancer cells, our study provides a novel and effective approach to inhibiting integrins by downregulating MMP-9, uPAR and cathepsin B in the treatment of glioma.
|
20657647 |
2010 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our previous work and that of others strongly suggest a relationship between the infiltrative phenotype of glioma and the expression of cathepsin B and uPAR.
|
20661471 |
2010 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Cystatin E/M is a potent inhibitor of cathepsin B, which is frequently overexpressed in glioma.
|
18607344 |
2008 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Given that sustained ATP release from glia upon injury greatly contributes to secondary brain damage and cathepsin B plays a critical role in glioma dissemination, TI-VAMP silencing can represent a novel strategy to control lysosome fusion in pathological conditions.
|
22188132 |
2012 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Glioma spheroids expressed higher levels of cathepsin B than did monolayers and the ability of subclones differing in cathepsin B activity to infiltrate normal brain aggregates paralleled their cathepsin B activity.
|
10571410 |
1999 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We have shown previously that urokinase plasminogen activator receptor (uPAR) and cathepsin B are overexpressed during glioma progression, particularly at the leading edge of the tumor.
|
15205313 |
2004 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Cathepsin B expression and localization in glioma progression and invasion.
|
7954439 |
1994 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, IL-1β, phosphorylated Akt, and cathepsin B proteins were also reduced in MSC/glioma.
|
23034897 |
2013 |
|
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma.
|
21394106 |
2011 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma.
|
10701774 |
2000 |